International Journal of Celiac Disease
ISSN (Print): 2334-3427 ISSN (Online): 2334-3486 Website: Editor-in-chief: Samasca Gabriel
Open Access
Journal Browser
International Journal of Celiac Disease. 2016, 4(2), 40-47
DOI: 10.12691/ijcd-4-2-2
Open AccessArticle

The Effect of Enzyme Supplementation on Symptoms and Duodenal Histology in Celiac Patients

Hugh J. Cornell1, Agnieszka Czyzewska2, Finlay A. Macrae3, , Grazyna Rydzewska4, Anna Nasierowska-Gutmejer4, Arkadiusz Bednarczuk2 and Teodor Stelmasiak5

1Applied Chemistry, School of Applied Sciences, RMIT University, Melbourne, Australia

2Department of Internal Medicine and Gastroenterology, Central Clinical Hospital of Ministry of Interior, Warsaw, Poland

3Department of Colorectal Medicine & Genetics and Department of Medicine, University of Melbourne, The Royal Melbourne Hospital, Melbourne, Australia

4Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland

5Glutagen Pty Ltd, Maribyrnong, Australia

Pub. Date: May 28, 2016

Cite this paper:
Hugh J. Cornell, Agnieszka Czyzewska, Finlay A. Macrae, Grazyna Rydzewska, Anna Nasierowska-Gutmejer, Arkadiusz Bednarczuk and Teodor Stelmasiak. The Effect of Enzyme Supplementation on Symptoms and Duodenal Histology in Celiac Patients. International Journal of Celiac Disease. 2016; 4(2):40-47. doi: 10.12691/ijcd-4-2-2


Background: The etiology of celiac disease (CD) is related to undigested fragments of gluten and gliadin which damage the small bowel. Mucosal enzyme deficiency is an important factor in CD pathology. A clinical trial has shown that the effects of a gluten challenge to patients with CD could be ameliorated by the use of an enzyme supplement. Objective: Enzyme therapy using enterically coated tablets containing caricain (Gluteguard) was investigated as a means of protecting patients with CD against wheat gluten. Methods: A randomized placebo-controlled trial was carried out on 20 CD patients in clinical remission. The patients were divided into a group of 14 given Gluteguard and a group of 6 given a placebo daily. Both groups were given a challenge of 1g of gluten daily. Symptoms were graded and recorded over a period of 42 days. Duodenal tissue was taken at the beginning and end of this period, together with blood for assay of tissue transglutaminase (tTG-IgA) antibodies. Results: The results showed that oral enzyme therapy based on caricain, was effective in ameliorating the symptoms of CD giving a statistically significant difference between treatment and placebo (P<0.01) after 14 days challenge. General well-being was also improved from 6.1 to 8.4 (P< 0.01) by the enzyme therapy. Four of the six placebo group patients (67%) and one of the 14 treatment patients (7%) to withdraw from gluten challenge after 14 days due to development of serious symptoms. The difference between the groups was significant (p < 0.001). For the per protocol patients on Gluteguard therapy, there were no significant changes in markers of histological damage or biopsy results after 42 days of gluten challenge. Conclusions: This study demonstrated that oral anti-gluten enzyme therapy using Gluteguard was able to significantly protect celiac patients from adverse symptoms being induced by gluten challenge. Furthermore, mucosal damage was not exacerbated in patients taking Gluteguard along with their daily gluten challenge, suggesting that the enzyme tablets may also help with the recovery of epithelium in the longer term. Availability of a preventative enzyme treatment like Gluteguard will likely add to the quality of life and well-being of coeliac patients, especially those who have difficulty in strictly adhering to a gluten-free diet.

coeliac disease gluten caricain enzyme therapy Gluteguard

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Mendoza, N and McGough, N. (2005). Coeliac disease: an overview. Nutrition & Food Science, 35(3), 156-162.
[2]  Thompson, T. (1997). Do Oats Belong in a Gluten-Free Diet? Journal of the American Dietetic Association, 97(12, 1413-1416.
[3]  Rubio-Tapia, A., Ludvigsson, J.F., Brantner, T.L. Murray, J.A., & Everhart, J.E. (2012). The prevalence of celiac disease in the United States. Am J Gastroenterol, 107(10).
[4]  van Heel DA., West J. (2006). Recent advances in celiac disease. Gut 55: 1037-46.
[5]  Rubio-Tapia A, Kyle RA, Kaplan EL et al. (2009). Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 137: 88-93.
[6]  Metzer MH, Heier M, Maki M et al. (2006). Mortality excess in individuals with elevated IgA antitransglutaminase antibodies. Eur J Epidemiol 21: 359-65.
[7]  Grodzinsky, E., Franzen, L., Hed, J., & Strom, M. (1992). High prevalence of celiac-disease in healthy-adults revealed by antigliadin antibodies. Annals of Allergy, 69(1), 66-70.
[8]  Rubio-Tapia A, Rahim MR, See JA, Lahr BD, Wu TT, Murray JA. (2010) Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol. 105: 1412-1420.
[9]  Bardella MT, Velio P, Cesana BM, Prampolini L, Casella G, Di Bella C, Lanzini A, Gambarotti M, Bassotti G. Villanacci V. (2007). Coeliac disease: a histological follow-up study. Histopathology 50: 465-471.
[10]  Pekki H, Kurppa K., Maki M, Huhtala H, Sievanen H, Laurila K, Collin P, Kaukinen K. (2015). Predictors and significance of incomplete mucosal recovery in celiac disease after 1 year on a gluten-free diet. Am J Gastroenterol 110: 1078-1085.
[11]  Cornell H.J., Macrae F.A., Melny J., Pizzey C.J., Cook F., Mason S., Bhathal P.S., Stelmasiak, T. (2005). Enzyme therapy for management of celiac disease. Scandinavian Journal of Gastroenterology, 40(11), 1304-1312.
[12]  Stepniak D, Spaenij-Dekking L., Mitea C., Moester M., de Ru A., Baak-Pablo R. (2006). Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 291: G621-G629.
[13]  Cornell, HJ & Stelmasiak, T. (2011). Caricain: A basis for enzyme therapy for celiac disease. South African Journal of Science, 107(9-10).
[14]  Zebrowska, A, Cornell, H J., Macrae, F A., Sysa-Jedrzejowska, A, Waszczykowska, E & Stelmasiak, T. (2014). The Effect of Enzyme Therapy on Skin Symptoms and Immune Responses in Patients with Dermatitis Herpetiformis. International Journal of Celiac Disease, 2(2), 58-63.
[15]  Buddrick, Oliver, Cornell, Hugh J., & Small, Darryl M. (2015). Reduction of toxic gliadin content of wholegrain bread by the enzyme caricain. Food Chemistry, 170(0), 343-347.
[16]  Brocklehurst, K., Willenbrock, F., Salib E. (1987). p. 39-158. Cysteine proteinases, in Hydrolytic enzymes, Neuberger A, Brockenhurst K. eds. Amsterdam Elsevier Biomedical Press.
[17]  Berti, P.J. and A.C. Storer. (1995). Alignment/phylogeny of the papain superfamily of cysteine proteases. J Mol.Biol. 246: 273-283.
[18]  Haush F, Shan L, Santiago NA, Grey GM, Khosla C. (2002). Intestinal digestive resistance of immunodominant gliadin peptides. Am.J.Physiol.Gastrointest. & Liver Physiol. 283: G996-1003.
[19]  Shan, L., Molberg, O., Parrot, I., Hausch, F., Filiz, F., Gray, G.M., Khosla, C. (2002). Structural basis for gluten intolerance in celiac sprue. Science, 297(5590), 2275-2279.
[20]  Marsh MN. (1990).Grains of truth: evolutionary changes in small intestinal mucosa in response to environmental antigen challenge. Gut. 31:111–114.
[21]  Bailey N.T.J. (1959), Statistical Methods in Biology p.48. London: The English Universities Press.
[22]  Biagi F., Campanella J., Martucci S., Pezzimenti D., Cielitira P.J., Ellis H.J., Corazza M. (2004). A milligram of gluten a day keeps the mucosal recovery away: A case report. Nutrition Reviews. 62: 360-363.
[23]  Lewis HM. Reunala TL. Garioch JJ, Leonard JN, Fry JS, Collin P, Evans D, Fry L. (1996). Protective effect of gluten free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol 1996 135: 363-367.